Diagnostic and clinical significance of Crohn's disease-specific pancreatic anti-GP2 and anti-CUZD1 antibodies
dc.creator | Pavlidis P., Komorowski L., Teegen B., Liaskos C., Koutsoumpas A.L., Smyk D.S., Perricone C., Mytilinaiou M.G., Stocker W., Forbes A., Bogdanos D.P. | en |
dc.date.accessioned | 2023-01-31T09:46:32Z | |
dc.date.available | 2023-01-31T09:46:32Z | |
dc.date.issued | 2016 | |
dc.identifier | 10.1515/cclm-2015-0376 | |
dc.identifier.issn | 14346621 | |
dc.identifier.uri | http://hdl.handle.net/11615/77997 | |
dc.description.abstract | Background: Pancreatic autoantibodies (PAB) targeting GP2 and CUZD1 are Crohn's disease (CrD)-markers. The clinical significance of anti-GP2 antibodies has been assessed, but that of anti-CUZD1 remains elusive. The aim of the study was to assess the clinical utility of anti-CUZD1/anti-GP2 by novel cell-based indirect immunofluorescence (IIF) assays in CrD. Methods: A total of 212 CrD and 249 UC patients followed up at a London IBD centre were investigated to simultaneously detect PABs, anti-GP2 and anti-CUZD1 by IIF using primate pancreatic tissue, and HEK293 over-expressing CUZD1 or GP2. Results: Overall, 88 (41.5%) CrDs compared to 26 (10.4%) UCs (p<0.001) tested positive for IgA and/or IgG anti-GP2 and/or anti-CUZD1 antibodies, while ASCA were found in 67.5% CrDs versus 19.2% UCs (p<0.0001); ASCA and/or PAB (anti-GP2 or anti-CUZD1) were detected in 76% CrD versus 34% UC patients. IgG anti-GP2 antibodies were less prevalent in L2 phenotype (p=0.002) and more prevalent in patients with stricturing disease (p=0.0418), even when a higher cut-off (≥1000 RU) was used (p=0.0396). Also, anti-GP2 IgG positive CrD patients had younger age of disease onset. IgA and/or IgG ASCA and anti-GP2 IgG antibody positive CrDs had younger onset of disease (p<0.0001), were more likely to have both ileal and colonic disease (p<0.0001) and had more stricturing (p<0.0001) than seronegative patients. Clinical correlates were not found for anti-CUZD1 positivity. Conclusions: PAB testing increases ASCA's serological sensitivity for CrD. Anti-GP2 detection, in isolation or in combination with ASCA, stratify CrD patients who phenotypically are characterised by a much younger onset of disease, extensive and stricturing behaviour. © 2016 by De Gruyter 2016. | en |
dc.language.iso | en | en |
dc.source | Clinical Chemistry and Laboratory Medicine | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84955267341&doi=10.1515%2fcclm-2015-0376&partnerID=40&md5=69cd24c9fb2f28daaf0e4337fe3bdf06 | |
dc.subject | bacterium antibody | en |
dc.subject | CUB and zona pellucida like domains-containing protein 1 antibody | en |
dc.subject | immunoglobulin A | en |
dc.subject | immunoglobulin G | en |
dc.subject | protein antibody | en |
dc.subject | Saccharomyces cerevisiae antibody | en |
dc.subject | unclassified drug | en |
dc.subject | zymogen granule glycoprotein 2 antibody | en |
dc.subject | antibody | en |
dc.subject | autoantibody | en |
dc.subject | biological marker | en |
dc.subject | CUZD1 protein, human | en |
dc.subject | glycoprotein-2, pancreas | en |
dc.subject | immunoglobulin A | en |
dc.subject | immunoglobulin G | en |
dc.subject | membrane protein | en |
dc.subject | recombinant protein | en |
dc.subject | adult | en |
dc.subject | antibody specificity | en |
dc.subject | Article | en |
dc.subject | colon disease | en |
dc.subject | controlled study | en |
dc.subject | Crohn disease | en |
dc.subject | diagnostic value | en |
dc.subject | female | en |
dc.subject | HEK293 cell line | en |
dc.subject | human | en |
dc.subject | ileum disease | en |
dc.subject | immunofluorescence | en |
dc.subject | major clinical study | en |
dc.subject | male | en |
dc.subject | pancreatic tissue | en |
dc.subject | phenotype | en |
dc.subject | priority journal | en |
dc.subject | United Kingdom | en |
dc.subject | biosynthesis | en |
dc.subject | blood | en |
dc.subject | chemistry | en |
dc.subject | Colitis, Ulcerative | en |
dc.subject | Crohn disease | en |
dc.subject | genetics | en |
dc.subject | immunology | en |
dc.subject | metabolism | en |
dc.subject | middle aged | en |
dc.subject | Saccharomyces cerevisiae | en |
dc.subject | Adult | en |
dc.subject | Antibodies | en |
dc.subject | Autoantibodies | en |
dc.subject | Biomarkers | en |
dc.subject | Colitis, Ulcerative | en |
dc.subject | Crohn Disease | en |
dc.subject | Female | en |
dc.subject | HEK293 Cells | en |
dc.subject | Humans | en |
dc.subject | Immunoglobulin A | en |
dc.subject | Immunoglobulin G | en |
dc.subject | Male | en |
dc.subject | Membrane Glycoproteins | en |
dc.subject | Membrane Proteins | en |
dc.subject | Middle Aged | en |
dc.subject | Phenotype | en |
dc.subject | Recombinant Proteins | en |
dc.subject | Saccharomyces cerevisiae | en |
dc.subject | Walter de Gruyter GmbH | en |
dc.title | Diagnostic and clinical significance of Crohn's disease-specific pancreatic anti-GP2 and anti-CUZD1 antibodies | en |
dc.type | journalArticle | en |
Αρχεία σε αυτό το τεκμήριο
Αρχεία | Μέγεθος | Τύπος | Προβολή |
---|---|---|---|
Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο. |